Ginkgo Bioworks Holdings Inc (DNA)

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug DiscoveryMay 26, 2026 12:33 PM
PR Newswire (US) New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identificationBOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management. The launch builds on the three companies' strategic partnership, announced in August 2025, to deploy AI-driven, lab-in-the-loop workflows across the biopharma industry.  ADME-One is designed to break a cycle that has constrained small molecule drug discovery for decades: Due to the economic limitations of traditional data generation methods, comprehensive ADME profiling is typically reserved for lead optimization after teams have determined their lead series. When liabilities surface at this later stage, the cost of fixing them is highest. ADME-One changes that calculus, allowing discovery teams to characterize entire series with integrated, data-driven decisions in stages as early as hit identification. The result is fewer surprises, fewer wasted synthesis cycles, and a better ability to identify and test the compounds most likely to succeed in humans.A Single, Integrated Workflow Across Three Category LeadersADME-One unites three best-in-class capabilities in one packaged service:Ginkgo Datapoints: Data Generation. All five Tier 1 assays (microsomal stability, cell permeability, kinetic solubility, CYP inhibition, and plasma protein binding) are executed end-to-end in Ginkgo's automated laboratory in Boston. Validated, standardized workflows produce AI-ready data without the variability of manual handling.Inductive Bio: AI-Driven Contextualization. Inductive Bio's Compass platform turns the experimental panel into actionable human PK projections, integrating disparate individual ADME datapoints into a single multiparameter optimization endpoint that guides compound prioritization. The company's ADMET models are independently validated as best-in-class, having recently won both the 2025 ASAP and 2026 ExpansionRx OpenADMET blind prediction challenges, two of the most rigorous public benchmarks in the field.Tangible Scientific: Compound Management. Customers submit compounds and receive results. Tangible handles compound intake, plating, real-time tracking, and management for every ADME-One order, eliminating the logistics overhead that typically accompanies outsourced ADME work.Impact on Drug Discovery"With ADME-One, we're both lowering the price of an ADME panel and transforming when and to what extent this data is effectively used in the drug discovery process," said John Androsavich, General Manager at Ginkgo Datapoints. "For the first time, chemists can efficiently characterize the entire series in hit identification. That fundamentally changes the quality of decisions teams make at the earliest stages of a program, where derisking is most needed. By combining automation, AI, and integrated logistics in a single domestic workflow, Ginkgo and our partners are demonstrating and making available the workflows that the Bio × AI era of drug discovery demands.""We are at a moment in the application of AI to medicine where discovery teams can generate and prioritize drug candidates faster than their physical operations can validate them. Manifests get reconciled by hand, orders move through email threads, and senior scientists spend hours per week chasing shipments and tracking inventory across vendors. Tangible's role in ADME-One is to make the handoffs between design and data disappear, so discovery teams can validate candidates at the speed their AI investments promised," said Adham Chebbani, Co-founder of Tangible Scientific."The question every drug program is really trying to answer is which compound is most likely to achieve a safe and efficacious human dose," said Josh Haimson, CEO at Inductive Bio. "The Inductive platform lets drug hunters rank millions of compounds by predicted human dose, using state-of-the-art AI models that placed first in both OpenADMET competitions. With ADME-One, we move those compounds from the virtual lab to the wet lab in a tight feedback loop, surfacing the most promising ideas from day one. This is what AI-driven discovery looks like in practice: better decisions earlier, fewer dead ends later, and higher-quality medicines reaching patients sooner."Together, the three partners deliver unified, contextualized ADME data in a streamlined workstream with rapid turnaround, all at a price point several times lower than the industry standard. Against the backdrop of U.S. and European drug developers reshoring preclinical efforts in response to the BIOSECURE Act and growing demand for data sovereignty, ADME-One delivers a fully U.S.-based workflow at pricing that beats offshore alternatives. Automated workflows return results in days rather than weeks, and because every run is standardized, each screening campaign contributes to better future predictions, delivering the volume, consistency, and metadata richness that AI-driven discovery depends on.To drive ADME-One's product strategy, Ginkgo Datapoints has added Jonathan Grob to its leadership team as Vice President of Small Molecules. Grob brings deep expertise in medicinal chemistry, automation, and technology development from prior roles at Novartis and Valo Health. His hire reflects Ginkgo's continued investment in building the strongest next-generation, AI-enabled small molecule drug discovery team in the industry, complementing the platform's automation and data generation capabilities with seasoned scientific leadership.Get Started on ADME-OneDrug discovery teams interested in early access or volume engagements are encouraged to contact Ginkgo Datapoints, Tangible Scientific, or Inductive Bio directly. Existing customers can contact their account representative to enable access to ADME-One. New customers can email datapoints@ginkgobioworks.com and visit our website at https://datapoints.ginkgo.bio/services#small-molecule-adme The three partners host the New England Drug Metabolism Discussion Group (NEDMDG) meeting on May 27 in Boston where they will share additional technical details, validation data, and customer case studies.About Ginkgo BioworksGinkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.About Tangible ScientificTangible Scientific is a tech-enabled compound management platform that removes the logistics bottleneck between design and data. From its Natick, MA facility, Tangible takes operational custody of customer compounds, handling storage, reformatting, plating, and same-day courier service to Boston-area partners including Ginkgo. AI-powered manifest reconciliation, real-time order tracking, and structured data return run through a single interface, giving discovery teams the quality of an in-house compound operation without the cost of building one. For more information, visit tangiblescientific.com.About Inductive BioInductive builds virtual chemistry labs that help drug hunters design higher quality molecules, faster. Inductive's virtual labs are designed to scale proven scientific best practices across medicinal chemistry, computational chemistry, DMPK, and safety, enabling teams to make higher-quality decisions consistently throughout discovery. Inside these virtual labs, AI chemistry assistants, predictive ADMET and PK models, and human-relevant digital organ technologies work together to help scientists evaluate more hypotheses in silico and surface key risks earlier. The most promising molecules move from the virtual lab to the wet lab in a tight feedback loop that accelerates the advancement of high-quality molecules. Inductive already powers dozens of active discovery programs, including collaborations with leading biopharma partners. For more information, please visit www.inductive.bio.Forward-Looking Statements of Ginkgo BioworksThis press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's autonomous labs. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.INDUCTIVE BIO MEDIA CONTACT: media@inductive.bio View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-datapoints-tangible-scientific-and-inductive-bio-launch-adme-one-a-high-throughput-adme-platform-that-brings-pharmacokinetic-projection-earlier-in-drug-discovery-302782095.htmlSOURCE Inductive Bio, Inc. Original: Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

The $59B Quiet Shift Reshaping How Patients Access CareMay 12, 2026 10:30 AM
PR Newswire (US) Issued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and five names sit at the center of that structural realignment: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Hims & Hers Health (NYSE: HIMS), Novo Nordisk (NYSE: NVO), MannKind (NASDAQ: MNKD), and Ginkgo Bioworks (NYSE: DNA).  The trajectory keeps steepening. Analysts project the global POC diagnostics market will reach $114.65 billion by 2035, fueled by AI integration, miniaturized biosensors, and cloud-connected platforms that compress turnaround times from days to minutes[3]. The entire diagnostic equipment value chain is shifting from a centralized hospital model to a decentralized, consumer-facing landscape, and that creates a scalable opening for platforms delivering accessible, clinical-grade outcomes outside traditional hospital walls.VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is heading to Europe next week to showcase its AI-powered cardiac imaging platform at one of the biggest cardiology conferences on the planet. The company will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), running May 12 to 16 in Padua, Italy, alongside European distributor AngioPro. AEPC is the world's largest association in congenital cardiology, with over 1,000 specialists across 32 countries, and this year's program is centered on cardiovascular imaging and artificial intelligence, exactly the areas where VentriPoint operates.VMS+™ 4.0 takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to cardiac MRI, but without the million-dollar machine or the months-long wait list. Built on more than a decade of proprietary Knowledge Based Reconstruction technology, the system works with ultrasound equipment from any manufacturer and holds regulatory approvals in the United States, Canada, and Europe.That regulatory footprint is expanding. In late April, VentriPoint announced that strategic partner Lishman Global Inc. formally submitted VMS+™ 4.0 to China's National Medical Products Administration (NMPA) for approval. Lishman Global qualified for the NMPA's expedited "green channel" review pathway, reserved for innovative technologies addressing significant clinical needs. China has an estimated 330 million patients affected by cardiovascular disease.Commercial momentum has been building. VentriPoint recently picked up a Gold Medal at the 2026 Edison Awards for VMS+™ 4.0. It announced a collaboration with the Health Division of the Montecristo Group to deploy VMS+™ across Costa Rica's hospital networks, where Hospital Metropolitano has an existing relationship with Sanford Health. VentriPoint also recently partnered with First Light Health to bring cardiac diagnostics to Indigenous and remote communities across Canada, building on an earlier partnership with the Nisga'a Valley Health Authority. The company also signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," said Hugh MacNaught, President and CEO of VentriPoint. "VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI, giving clinicians the confidence they need to manage their patients at every stage of life."With regulatory submissions advancing in China, distribution partners spanning Costa Rica to Northern California, Edison Award recognition, and a growing presence at major cardiology conferences, VentriPoint is building the kind of global footprint that turns a promising medtech platform into a scalable business.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/Other industry developments and happenings in the market include:Hims & Hers Health (NYSE: HIMS) announced a new collaboration with Novo Nordisk to make a broad assortment of FDA-approved GLP-1 medications available to eligible customers, including Wegovy, the only FDA-approved GLP-1 weight loss pill. The expansion positions Hims & Hers Health as the largest global consumer health platform for affordable access to approved medications, with prices starting as low as $149 a month."Today we're taking an important next step toward building a better model of healthcare that works for everyday people," said Andrew Dudum, co-founder and CEO of Hims & Hers Health. "When healthcare innovators work together, we can make sure customer access moves at the same speed as innovation. As the largest global consumer health platform, we're thrilled to be working alongside Novo Nordisk to help more people feel their best and we're excited to find more ways to collaborate across the industry."Novo Nordisk (NYSE: NVO) is expanding patient reach through the partnership, with eligible customers now able to access treatments that can help them lose up to 20% of their body weight. Multiple Wegovy dosing options are available across both injectable and pill formats, alongside Ozempic injection pens approved for Type 2 diabetes treatment."Obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient," said Dr. Craig Primack, SVP Weight Management at Hims & Hers Health. "As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We're excited to see how our customers succeed as more innovative treatments become available."MannKind (NASDAQ: MNKD) announced it will present new clinical data on Afrezza at the ATTD 2026 conference in Barcelona, spanning oral and poster sessions focused on real-world dosing patterns and post-prandial glucose management in both adult and pediatric patients with type 1 diabetes. The presentations include findings from the INHALE-1 study, which examined how inhaled insulin is initiated and adjusted in children and adolescents, with patients started at an approximately 2:1 conversion from rapid-acting insulin analogs."We look forward to presenting important new data for Afrezza at this year's ATTD and contributing to the scientific dialogue around meal-time diabetes management across both adult and pediatric populations," said Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head, Diabetes for MannKind. "ATTD is a key forum for advancing how clinicians think about insulin use at meals, and we value the opportunity to engage with the global diabetes community on this important topic."The FDA accepted a supplemental Biologics License Application for Afrezza in patients ages 4-17 living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, Afrezza would become the first needle-free insulin option for pediatric patients in over 100 years.Ginkgo Bioworks (NYSE: DNA) launched Ginkgo Cloud Lab, a browser-based interface that gives researchers remote access to the company's autonomous lab infrastructure powered by proprietary Reconfigurable Automation Carts. The platform connects scientists to a fleet of over 70 instruments spanning sample preparation, liquid handling, analytical readouts, storage, and incubation, with an AI-driven agent called EstiMate enabling protocol submission in plain language and immediate compatibility assessment and pricing."Autonomous labs are poised to scale and accelerate the high-mix work that a lab bench supports," said Jason Kelly, CEO of Ginkgo Bioworks. "By opening up our autonomous infrastructure through the Cloud Lab, we're giving scientists access to these tools today."Ginkgo Cloud Lab is central to Ginkgo Bioworks' 2026 strategic shift to consolidate all R&D services onto Nebula, its autonomous lab in Boston, MA, decommissioning traditional benches in favor of programmable robotic infrastructure. The company is targeting users ranging from academic researchers to global biopharmaceutical companies, inviting them to submit protocols directly at cloud.ginkgo.bio for feasibility reports and price quotes.Further Reading: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/CONTACT:
Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.mordorintelligence.com/industry-reports/point-of-care-diagnosticshttps://www.medtechdive.com/news/digital-health-funding-concentrates-fewer-startups-q1-2026-rock-health/816933/ https://www.globenewswire.com/news-release/2026/04/30/3285062/0/en/Global-Point-of-Care-Diagnostics-Market-Size-Set-to-Reach-USD-114-65-Billion-by-2035-SNS-Insider.html Logo: https://mma.prnewswire.com/media/2840019/Equity_Insider_Logo.jpg View original content:https://www.prnewswire.com/news-releases/the-59b-quiet-shift-reshaping-how-patients-access-care-302769492.html Original: The $59B Quiet Shift Reshaping How Patients Access Care

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous LabMay 7, 2026 4:05 PM
PR Newswire (US) Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity businessBOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. First Quarter 2026 Financial ResultsAs previously announced, Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026 and is presenting the financial results of operations for the former business within discontinued operations.  Accordingly, Ginkgo's previously reported financial results for comparable periods have been retrospectively recast to conform to this presentation and reflect Ginkgo as a single reporting segment.First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%. As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities.First quarter 2026 GAAP net loss from continuing operations of $(76) million, compared to $(83) million in the comparable prior year period.First quarter 2026 Adjusted EBITDA of $(42) million, down from $(44) million in the comparable prior year period.Cash, cash equivalents and marketable securities balance as of March 31, 2026 of $373 million."We believe autonomous labs will replace the lab bench more quickly than people think," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "Nebula is already the world's largest autonomous lab with the ability to run real customer science around the clock and we're targeting to double its size this year. We see a large market that remains overwhelmingly manual today, and every experiment our Solutions, Datapoints, and Cloud Lab businesses run on Nebula generates revenue today while making the platform better for tomorrow. Ginkgo is singularly focused on leading the transition from the lab bench to autonomous research infrastructure that runs 24/7 and integrates directly with the AI models transforming drug discovery and industrial biotechnology."Recent Business Highlights & Strategic PositioningWe believe that autonomous labs will replace the bench.The return on investment of the autonomous lab is clear for customers, with millions of square feet and tens of billions per year being spent on work happening at the lab benchThe autonomous lab is a machine that can run 24/7 and can be seamlessly integrated into emerging AI modelsNebula, our autonomous lab, is showing what is possible at the bleeding edge.Nebula is the world's largest autonomous lab and in 2026 we are aiming to double its sizeRecent coverage positions Ginkgo at the frontier of scientific innovation in the scientific (Nature), trade (R&D World), mainstream (Forbes, The Washington Post), and tech press (Sequoia's Training Data, TBPN)Policymakers and heads of R&D visit for our internal demonstrations. During SLAS 2026, over 500 visitors came to tour NebulaCloud Lab, Datapoints, and Solutions are our version of Starlink.They both create revenue and speed the development of the autonomous labWe are seeing traction with our Cloud Lab from partners such as ProQR and Amazon, who included us as an integrated wet lab partner on their Amazon Bio Discovery platformFull Year 2026 OutlookGinkgo reaffirms expected total cash burn of $(150)-$(125) million in 2026.  Conference Call Details
Ginkgo will host a videoconference today, Thursday, May 7, beginning at 4:30 p.m. ET. The presentation will include an overview of the first quarter 2026, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session. To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/Audio-Only Dial Ins:+1 646 876 9923 (New York - ET)
+1 301 715 8592 (Washington DC - ET)
+1 305 224 1968 (Miami - ET)
+1 689 278 1000 (Orlando - ET)
+1 312 626 6799 (Chicago - CT)
+1 507 473 4847 (Minnesota - CT)
+1 346 248 7799 (Houston - CT)
+1 719 359 4580 (Colorado - MT)
+1 408 638 0968 (San Jose - PT)
+1 564 217 2000 (Seattle - PT)Webinar ID: 931 5925 7666If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.Forward-Looking Statements of Ginkgo Bioworks 
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as ProQR and Amazon), the anticipated growth, scaling, capacity, capabilities and competitive position of our autonomous lab (including Nebula) and of our Cloud Lab, Datapoints and Solutions offerings, our beliefs and estimates regarding the size, composition, growth and pace of adoption of the market for autonomous laboratory and related services (including the displacement of manual laboratory work), expectations regarding the development, performance and future enhancements of our platform, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook including the total cash burn guidance, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "target," "goal," "aim," "design," "forecast," "outlook," "guidance," "seek" "position," and similar expressions, as well as the negatives of such terms. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, and (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this release. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo does not reconcile its forward-looking non-GAAP financial measures to the corresponding GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information, such as unrealized equity gains and losses necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure, can be predicted with reasonable accuracy and is available to Ginkgo without unreasonable efforts. For the same reasons, Ginkgo is unable to address the probable significance of the unavailable information. Ginkgo provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the non-GAAP measures.Ginkgo Bioworks Contacts: INVESTOR CONTACT:
investors@ginkgobioworks.com MEDIA CONTACT:
press@ginkgobioworks.comGinkgo Bioworks Holdings, Inc.Condensed Consolidated Balance Sheets(unaudited)(in thousands, except share data)

As of March 31,
2026
As of December 31,
2025Assets


Current assets:


Cash and cash equivalents$             143,864
$             167,202Marketable securities229,592
255,418Accounts receivable, net19,815
24,026Accounts receivable - related parties454
229Prepaid expenses and other current assets16,230
24,963Total current assets409,955
471,838Property, plant and equipment, net163,020
167,371Operating lease right-of-use assets353,804
360,918Investments14,703
15,066Intangible assets, net48,860
53,482Other non-current assets39,522
47,167Assets held for sale3,211
3,854Total assets$           1,033,075
$           1,119,696Liabilities and Stockholders' Equity


Current liabilities:


Accounts payable$              16,309
$              10,566Deferred revenue (includes $98 and $98 from related parties)14,910
18,946Accrued expenses and other current liabilities48,376
66,458Total current liabilities79,595
95,970Non-current liabilities:


Deferred revenue, net of current portion (includes $64,810 and $64,787 from related
parties)77,895
75,182Operating lease liabilities, non-current410,700
417,078Other non-current liabilities21,732
22,876Total liabilities589,922
611,106Commitments and contingencies (Note 10)


Stockholders' equity:


Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued—
—Common stock, $0.0001 par value (Note 8)6
6Additional paid-in capital6,674,860
6,657,053Accumulated deficit(6,232,907)
(6,150,320)Accumulated other comprehensive income1,194
1,851Total stockholders' equity443,153
508,590Total liabilities and stockholders' equity$           1,033,075
$           1,119,696 Ginkgo Bioworks Holdings, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss(unaudited)(in thousands, except share data)

Three Months Ended March
31,
2026
2025Revenue (1)$        19,474
$        38,230



Costs and operating expenses:


Cost of other revenue3,098
4,090Research and development49,920
70,923General and administrative37,830
39,723Restructuring charges—
4,466Total operating expenses90,848
119,202Loss from operations(71,374)
(80,972)Other income (expense):


Interest income, net3,596
6,081Loss on investments(1,214)
(3,693)Other expense, net(7,147)
(4,638)Total other expense (4,765)
(2,250)Loss from continuing operations before income taxes(76,139)
(83,222)Income tax (benefit) expense(80)
88Net loss from continuing operations$       (76,059)
$       (83,310)Net loss from discontinued operations, net of tax(6,528)
(7,647)Net loss$       (82,587)
$       (90,957)Net loss per share:


Basic from continuing operations$           (1.28)
$           (1.54)Basic from discontinued operations(0.11)
(0.14)Basic$           (1.39)
$           (1.68)Weighted average common shares outstanding:


Basic59,563,454
54,241,619Comprehensive loss:


Net loss(82,587)
(90,957)Other comprehensive (loss) income:


Foreign currency translation adjustment(579)
849Unrealized gains (loss) on available-for-sale securities          (78)
107Total other comprehensive (loss) income(657)
956Comprehensive loss$       (83,244)
$       (90,001)
(1)  includes related party revenue of zero and $8,098 for the three months ended March 31, 2026 and 2025, respectively. Ginkgo Bioworks Holdings, Inc.Condensed Consolidated Statements of Cash Flows(unaudited)(in thousands)

Three Months Ended March 31,
2026
2025Cash flows from operating activities:


Net loss from continuing operations$       (76,059)
$       (83,310)Adjustments to reconcile net loss to net cash used in operating activities:


Depreciation and amortization12,799
14,822Stock-based compensation15,853
17,386Loss on investments1,214
3,693Change in fair value of notes receivable6,759
5,285Change in fair value of contingent consideration—
(1,302)Non-cash lease expense7,114
7,379Accretion of discount on marketable securities(120)
—Other non-cash activity185
149Changes in operating assets and liabilities:


Accounts receivable(242)
(667)Prepaid expenses and other current assets5,930
(581)Operating lease right-of-use assets—
3,675Other non-current assets94
(167)Accounts payable, accrued expenses and other current liabilities(11,601)
8,869Deferred revenue, current and non-current (includes zero and $(7,878) from related
parties)(2,606)
(13,190)Operating lease liabilities, current and non-current(4,995)
(4,790)Other non-current liabilities(758)
—Net cash used in operating activities - continuing operations(46,433)
(42,749)Net cash used in operating activities - discontinued operations(253)
(8,772)Net cash used in operating activities(46,686)
(51,521)Cash flows from investing activities:


Purchases of marketable debt securities(83,161)
(191,182)Maturities of marketable debt securities108,178
—Purchases of property and equipment(1,933)
(7,622)Other48
120Net cash provided by (used in) investing activities23,132
(198,684)Cash flows from financing activities:


Principal payments on finance leases(19)
(207)Net cash used in financing activities(19)
(207)Effect of foreign exchange rates on cash and cash equivalents(129)
74Net decrease in cash, cash equivalents and restricted cash(23,702)
(250,338)



Cash and cash equivalents, beginning of period167,202
561,572Restricted cash, beginning of period45,169
44,171Cash, cash equivalents and restricted cash, beginning of period212,371
605,743



Cash and cash equivalents, end of period143,864
312,420Restricted cash, end of period44,805
42,985Cash, cash equivalents and restricted cash, end of period$       188,669
$       355,405The following table presents summary results of the Company's reportable segment, including significant expenses, and a reconciliation to loss from continuing operations before income taxes (in thousands):
Three Months Ended March 31,
2026
2025Revenue$        19,474
$        38,230Costs and operating expenses:


   Cost of other revenue (1)2,672
3,121   Research and development (1)30,105
48,670   General and administrative (1)12,723
19,654Stock-based compensation (2)16,708
17,713Depreciation and amortization12,799
14,822Restructuring charges (3)—
4,466Carrying cost of excess space (net of sublease income) (4)15,842
11,674Merger and acquisition related expense (income) (5)—
(918)Other (income) expense, net (6)4,764
2,250Loss from continuing operations before income taxes$      (76,139)
$      (83,222)

(1)The costs and operating expenses exclude expenses which are separately captioned below.(2)Includes $0.9 million and $0.4 million in employer payroll taxes for three months ended March 31, 2026 and 2025, respectively.(3)See Note 3, Restructuring, for composition of costs.(4)The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.(5)Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs.(6)Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.


Three Months Ended March 31,(in thousands)2026
2025Net loss from continuing operations (1)$      (76,059)
$      (83,310)Interest income, net(3,596)
(6,081)Income tax (benefit) expense(80)
88Depreciation and amortization12,799
14,822EBITDA(66,936)
(74,481)Stock-based compensation (2)16,708
17,713Restructuring charges (3)—
4,466Merger and acquisition related (income) expense (4)          —
(918)Loss (gain) on investments1,214
3,693Change in fair value of notes receivable6,759
5,285Adjusted EBITDA$      (42,255)
$      (44,242)

(1)All periods include non-cash revenue when earned, including $7.5 million recognized in the three months ended March 31, 2025, pursuant to the release of deferred revenue related to the mutual termination of a customer agreement.(2)Includes $0.9 million and $0.4 million  in employer payroll taxes for the three months ended March 31, 2026 and 2025, respectively.(3)Restructuring charges primarily consist of employee termination costs from the reduction in force commenced in June 2024.(4)Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero for both the three months ended March 31, 2026 and 2025, respectively.  View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-reports-first-quarter-2026-financial-results-completes-divestiture-of-biosecurity-and-continues-to-scale-autonomous-lab-302766171.htmlSOURCE Ginkgo Bioworks Original: Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Ginkgo Bioworks Announces Date of First Quarter 2026 Results PresentationApril 30, 2026 8:01 AM
PR Newswire (US)

Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET.







The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a question ahead of the presentation, please submit them to @&h=159143176&u=https%3A%2F%2Ftwitter.com%2Fginkgo&a=Ginkgo" target="_blank" rel="nofollow">Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X ( @&h=3963092197&u=https%3A%2F%2Fx.com%2Fginkgo&a=Ginkgo" target="_blank" rel="nofollow">Ginkgo and @&h=975610442&u=https%3A%2F%2Fx.com%2FGinkgo_Biosec&a=Ginkgo_Biosec" target="_blank" rel="nofollow">Ginkgo_Biosec), Instagram ( @&h=1344639403&u=https%3A%2F%2Fwww.instagram.com%2Fginkgobioworks%2F&a=GinkgoBioworks" target="_blank" rel="nofollow">GinkgoBioworks), Threads ( @&h=3585895089&u=https%3A%2F%2Fwww.threads.com%2F%40ginkgobioworks&a=GinkgoBioworks" target="_blank" rel="nofollow">GinkgoBioworks), or LinkedIn.Ginkgo Bioworks Contacts: INVESTOR CONTACT:investors@ginkgobioworks.com MEDIA CONTACT:press@ginkgobioworks.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-date-of-first-quarter-2026-results-presentation-302757632.htmlSOURCE Ginkgo Bioworks

Original: Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation

DNA logo
Ginkgo Bioworks Holdings

NYSE:DNA

Published 13 Mar 2026

DNA: Future Returns Will Hinge On Monetizing Autonomous Labs By 2026
Analysts have trimmed their average price target for Ginkgo Bioworks Holdings, with cuts from $14 to $12 and from $9 to $5, reflecting reduced revenue growth assumptions, a slightly lower fair value estimate, and a higher discount rate as they wait for clearer progress on monetizing autonomous labs after the biosecurity divestiture. Analyst Commentary Bullish Takeaways Bullish analysts still see enough long term potential to maintain positive ratings, even as they trim price targets to US$12 from US$14.

AnalystConsensusTarget's avatar
AnalystConsensusTarget

Based on Analyst Price Targets

Fair Value

US$8.67

Fair Value decreased 13%
Last price US$6.49 | 25.1% undervalued

Based on -3.48% p.a. revenue growth for 3 years

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity BusinessFebruary 26, 2026 4:26 PM
PR Newswire (US)

Ginkgo provides an update on its fourth quarter financial resultsBOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.







Fourth Quarter 2025 Financial ResultsFourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year period, Total revenue in the fourth quarter of 2025 decreased 24% from the comparable prior year period.Fourth quarter 2025 Cell Engineering revenue of $26 million compared to $35 million in the comparable prior year period, a decrease of 26%Fourth quarter 2025 Biosecurity revenue of $7 million compared to $9 million in the comparable prior year periodFourth quarter 2025 GAAP net loss of $(81) million, compared to $(108) million in the comparable prior year periodFourth quarter 2025 Adjusted EBITDA of $(36) million, up from $(57) million in the comparable prior year period, primarily attributable to the decrease in operating expenses in the prior year periodCash, cash equivalents and marketable securities balance as of December 31, 2025 of $423 million"This year, we are going to focus on investing to win in the category of autonomous labs," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "There is an emerging wave of interest in robotics and AI, and our work with the Department of Energy and OpenAI this year shows that Ginkgo is in the best position to bring robotics to an extraordinarily high value area: laboratory research."Full Year 2025 Financial ResultsFull year 2025 Total revenue of $170 million, down from $227 million in the prior year, a decrease of 25% driven by the shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuring. Full year 2025 and 2024 also benefited from $8 million and $45 million of non-cash revenue from previously announced releases of deferred revenue relating to the mutual terminations of customer agreements.Full year 2025 Cell Engineering revenue of $133 million, down from $174 million in the prior year, a decrease of 24%. Excluding the non-cash deferred revenue releases discussed above, full year 2025 and 2024 Cell Engineering revenue of $125 million and $129 million, respectively, with 2025 Cell Engineering revenue decreasing 3%, primarily attributed to ongoing program rationalization as part of our restructuring activities. Full year 2025 Biosecurity revenue of $37 million, down from $53 million in the prior year, a decrease of 30%, with full year 2025 Biosecurity gross profit margin of 23%Full year 2025 GAAP net loss of $(313) million, compared to $(547) million in the prior yearFull year 2025 Adjusted EBITDA of $(167) million, improved from $(293) million in the prior yearBiosecurity Business DivestitureGinkgo today announced it has reached an agreement to sell the Company's biosecurity business to a consortium of investors ("Investors") in exchange for a minority equity position in the business alongside the Investors. Upon completion, the biosecurity business will operate as a standalone private entity focused on building a scaled, biosecurity infrastructure platform for the United States and its global partners. The transaction provides the biosecurity business with greater flexibility and additional resources to pursue near- and long-term growth opportunities. Per Ginkgo CEO Jason Kelly, "There is rising interest in defense tech in private capital markets and spinning off our biosecurity business into a private entity with new investors allows it to grow faster with more investment than it would inside Ginkgo. This serves Ginkgo in two ways: we are able to participate in the upside of the new entity as a shareholder but importantly we also focus Ginkgo's cash investment on our autonomous labs business."Ginkgo expects to complete the transaction in the first half of 2026, subject to the satisfaction of customary closing conditions.Recent Business Highlights & Strategic PositioningWe are making 2026 a year of investment in our autonomous labThis year, we will focus Ginkgo's efforts on autonomous labs as the common platform for biotechnology research and invest to extend our current lead in technology. We are currently expanding our frontier autonomous lab in Boston to include over 50 RACs, with 50 more expected by the end of the yearWe will demonstrate the capabilities of autonomous labs by decommissioning the majority of Ginkgo's lab benches, walk-up automation, and workcells and moving our three R&D services businesses onto a single, large autonomous labWe are commercializing our autonomous lab through two distinct pathways: through our cloud lab services and by building autonomous labs for customersWe just released the results of a collaboration with OpenAI where they used GPT-5 to design experiments using Ginkgo's cloud lab. This resulted in achieving a 40% improvement over the state-of-the-art in Cell-Free Protein SynthesisAfter a pilot, we build and install customized autonomous systems directly at customer sites, allowing them to run workflows in a matter of weeks. We did this for the Pacific Northwest National Laboratory, where we recently dedicated an 18-instrument autonomous anaerobic system and won a $47M contract for a 97-instrument autonomous labGinkgo continues to hold a strong cash position while winning new deals across Agriculture, Pharma, and the U.S. Government, providing a strong revenue base to position for future growthWe ended 2025 with $423 million in cash, cash equivalents and marketable securitiesDatapoints defined the category of Bio-AI Data Provider, worked with 10 top pharma customers in its first full year.In the fourth quarter of 2025, Solutions announced partnerships with ARPA-H, University of Illinois Urbana-Champaign, Carnegie Mellon, Agricen, Deep Origin and moreFull Year 2026 OutlookGinkgo expects total cash burn of $(150)-$(125) million in 2026. Conference Call DetailsGinkgo will host a videoconference today, Thursday, February 26, beginning at 4:30 p.m. ET. The presentation will include an overview of the fourth quarter and full year 2025, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/Audio-Only Dial Ins:+1 646 876 9923 (New York - ET)
+1 301 715 8592 (Washington DC - ET)
+1 305 224 1968 (Miami - ET)
+1 689 278 1000 (Orlando - ET)
+1 312 626 6799 (Chicago - CT)
+1 507 473 4847 (Minnesota - CT)
+1 346 248 7799 (Houston - CT)
+1 719 359 4580 (Colorado - MT)
+1 408 638 0968 (San Jose - PT)
+1 564 217 2000 (Seattle - PT)
Webinar ID: 931 5925 7666If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.Forward-Looking Statements of Ginkgo Bioworks
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures.Ginkgo Bioworks Contacts: INVESTOR CONTACT:
investors@ginkgobioworks.com MEDIA CONTACT:
press@ginkgobioworks.comGinkgo Bioworks Holdings, Inc.Consolidated Balance Sheets (in thousands, except share data) 
As of December 31,
2025
2024Assets


Current assets:


Cash and cash equivalents$      167,202
$      561,572Marketable securities255,418
—Accounts receivable, net24,026
21,857Accounts receivable - related parties229
586Prepaid expenses and other current assets24,963
18,729Total current assets471,838
602,744Property, plant and equipment, net167,783
203,720Operating lease right-of-use assets360,918
394,435Investments15,066
48,704Intangible assets, net56,924
72,510Other non-current assets47,167
55,336Total assets$   1,119,696
$   1,377,449Liabilities and Stockholders' Equity


Current liabilities:


Accounts payable$        10,566
$        14,169Deferred revenue (includes $98 and $795 from related parties)18,946
27,710Accrued expenses and other current liabilities66,458
65,387Total current liabilities95,970
107,266Non-current liabilities:


Deferred revenue, net of current portion (includes $64,787 and $72,260 from related parties)75,182
98,783Operating lease liabilities, non-current417,078
438,766Other non-current liabilities22,876
16,576Total liabilities611,106
661,391Commitments and contingencies (Note 12)


Stockholders' equity:


Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued—
—Common stock, $0.0001 par value (Note 13)6
5Additional paid-in capital6,657,053
6,555,416Accumulated deficit(6,150,320)
(5,837,557)Accumulated other comprehensive income (loss)1,851
(1,806)Total stockholders' equity508,590
716,058Total liabilities and stockholders' equity$   1,119,696
$   1,377,449The accompanying notes are an integral part of these consolidated financial statements. Ginkgo Bioworks Holdings, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share data)   
Year Ended December 31,
2025
2024
2023Cell Engineering revenue (1)$        132,746
$        173,972
$        143,531Biosecurity revenue:




Service37,409
53,071
78,975Product—
—
28,949Total revenue170,155
227,043
251,455Costs and operating expenses:




Cost of Biosecurity service revenue31,521
38,549
46,524Cost of Biosecurity product revenue—
—
7,481Cost of other revenue15,451
5,999
—Research and development243,773
424,061
580,621General and administrative183,290
246,161
385,025Impairment of lease assets—
—
96,210Goodwill impairment—
47,858
—Restructuring charges11,398
24,172
—Total operating expenses485,433
786,800
1,115,861Loss from operations(315,278)
(559,757)
(864,406)Other income (expense):




Interest income22,616
38,612
57,217Interest expense—
(94)
(93)Loss on equity method investments—
—
(2,635)Loss on investments(16,411)
(28,827)
(54,827)Loss on deconsolidation of subsidiaries—
(7,013)
(42,502)Change in fair value of warrant liabilities—
5,701
5,168Other (expense) income, net(4,527)
3,870
9,138Total other income (expense)1,678
12,249
(28,534)Loss before income taxes(313,600)
(547,508)
(892,940)Income tax benefit(837)
(479)
(71)Net loss$      (312,763)
$      (547,029)
$      (892,869)Net loss per share$            (5.64)
$          (10.54)
$          (18.37)Weighted average common shares outstanding:55,457,676
51,894,639
48,610,507Comprehensive loss:




Net loss$      (312,763)
$      (547,029)
$      (892,869)Other comprehensive income (loss):




Foreign currency translation adjustment3,531
(4,782)
4,116Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary—
1,492
—Unrealized gain on available-for-sale securities126
—
—Total other comprehensive income (loss) 3,657
(3,290)
4,116Comprehensive loss$      (309,106)
$      (550,319)
$      (888,753)

(1)Includes related party revenue of $8,784, $53,041, and $22,222 for the years ended December 31, 2025, 2024, and 2023, respectively.The accompanying notes are an integral part of these consolidated financial statements.Ginkgo Bioworks Holdings, Inc.Consolidated Statements of Cash Flows (in thousands) 
Year Ended December 31,
2025
2024
2023Cash flows from operating activities:




Net loss$      (312,763)
$      (547,029)
$      (892,869)Adjustments to reconcile net loss to net cash used in operating activities:




Depreciation and amortization58,990
63,020
70,507Stock-based compensation81,546
112,344
229,884Goodwill impairment—
47,858
—Restructuring related impairment charges—
4,823
—Non-cash customer consideration—
(1,117)
(1,373)Loss on equity method investments—
—
2,635Loss on investments16,411
28,827
54,827Change in fair value of notes receivable5,685
2,014
2,416Change in fair value of warrant liabilities—
(5,701)
(5,168)Change in fair value of contingent consideration liability(4,232)
3,214
9,168Loss on deconsolidation of subsidiaries—
7,013
42,502Impairment of long-lived assets—
5,796
121,404Deferred income tax benefit(1,364)
(936)
(801)Loss on disposal of equipment—
844
842Non-cash lease expense30,082
28,095
28,313Non-cash in-process research and development—
19,796
9,182Accretion of discount on marketable securities(3,390)
—
—Other non-cash activity2,064
1,224
3,194Changes in operating assets and liabilities:




Accounts receivable ($357, $156 and $816 from related parties)(1,473)
(4,725)
50,068Prepaid expenses and other current assets(5,247)
10,085
10,473Operating lease right-of-use assets3,814
23,463
9,275Other non-current assets296
(1,394)
2,570Accounts payable(2,992)
4,771
(1,183)Accrued expenses and other current liabilities10,376
(40,438)
16,899Deferred revenue, current and non-current ($(8,147), $(51,422) and $(17,018) from related parties)(32,393)
(68,645)
(35,917)Operating lease liabilities, current and non-current(27,932)
(14,881)
(22,800)Other non-current liabilities11,463
2,094
452Net cash used in operating activities(171,059)
(319,585)
(295,500)Cash flows from investing activities:




Purchases of marketable debt securities(418,630)
—
—Maturities of marketable debt securities159,483
—
—Proceeds from sale of marketable debt securities25,899
—
—Purchases of property and equipment(7,665)
(62,541)
(40,801)Deconsolidation of subsidiaries - cash—
—
(42,980)Business acquisitions, net of cash acquired—
(5,400)
—Purchases of notes receivable—
—
(350)Proceeds from sales of marketable equity securities—
4,519
—Proceeds from sale of equipment574
648
4,428Other50
538
(990)Net cash used in investing activities(240,289)
(62,236)
(80,693)Cash flows from financing activities:




Proceeds from ATM offering19,469
—
—Payment of issuance costs related to ATM offering(1,340)
—
—Proceeds from exercise of stock options—
84
93Taxes paid related to net share settlement of equity awards—
—
(23)Principal payments on finance leases(354)
(897)
(1,295)Contingent consideration payment—
(922)
(1,411)Payment of equity issuance costs and other—
(4)
(580)Net cash provided by (used in) financing activities17,775
(1,739)
(3,216)Effect of foreign exchange rates on cash and cash equivalents201
(281)
(588)Net decrease in cash, cash equivalents and restricted cash(393,372)
(383,841)
(379,997)





Cash and cash equivalents, beginning of year561,572
944,073
1,315,792Restricted cash, beginning of year44,171
45,511
53,789Cash, cash equivalents and restricted cash, beginning of year605,743
989,584
1,369,581





Cash and cash equivalents, end of year167,202
561,572
944,073Restricted cash, end of year45,169
44,171
45,511Cash, cash equivalents and restricted cash, end of year$        212,371
$        605,743
$        989,584The accompanying notes are an integral part of these consolidated financial statements.16. Segment InformationThe Company operates in two operating and reportable segments: Cell Engineering and Biosecurity. This structure reflects the Company's internal management framework and the approach its CODM uses to evaluate operating results and allocate resources. The Company's reportable segments are described as follows:Cell Engineering consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological R&D. The Company's cell engineering platform includes R&D services (solutions) where Ginkgo performs technical activities.  Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart ("RAC") systems capable of large scale data generation; it powers generative AI and machine learning ("ML") tools that enable more successful biological R&D. We now offer services providing such data generation, AI and automation tools directly to Ginkgo customers. Cell Engineering revenue is generated primarily through R&D service fees for our solutions and Datapoints services; and design, build, installation and ongoing support fees for our automation solutions (RAC) systems. Historically our solutions deals also included downstream value share in the form of milestone payments, royalties or equity interests.Biosecurity consists of the Company's biomonitoring and bioinformatics support services, offered to both government and non-government customers through the Company's two core offerings: Canopy and Horizon. Biosecurity revenue is generated from fees for data, analytics, and services. Prior to 2024, Biosecurity revenue also included sales of COVID-19 diagnostic and sample collection test kits.The Company's reportable segments are those for which discrete financial information is available and whose results are regularly provided to the Company's CODM, consisting of the Chief Executive Officer and the Chief Operating Officer, for the purpose of allocating resources and assessing financial performance. The CODM evaluates the financial performance of the Company's segments based on segment operating income (loss). The CODM is primarily provided with the segment operating income (loss) on a quarterly basis, as well as during the annual budgeting and forecasting process, and uses this information to monitor the Company's performance, including budget-to-actual results, and to make decisions about the allocation of operating and capital resources to each segment. For management reporting purposes, the Company's measure of segment operating income (loss) excludes the impact of stock-based compensation expense, depreciation and amortization, asset impairment charges, restructuring charges, costs associated with excess space, transaction and integration costs associated with planned, completed or terminated mergers and acquisitions, and acquired in-process research and development expenses. The Company has determined its significant segment expenses are cost of revenue for Biosecurity, research and development expenses for Cell Engineering, and general and administrative expenses for both segments, which are regularly provided to the CODM.The CODM is not provided with asset information by segment; therefore, such information is not presented. The accounting policies used to prepare the reportable segments financial information are the same as those used to prepare the Company's consolidated financial statements.The following table presents summary results of the Company's reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):
Year Ended December 31,
2025
2024
2023Cell Engineering




Revenue$      132,746
$      173,972
$      143,531Costs and operating expenses:




   Cost of other revenue13,203
5,999
—   Research and development158,541
271,512
335,943   General and administrative56,532
115,028
171,210Cell Engineering operating loss(95,530)
(218,567)
(363,622)Biosecurity




Service revenue37,409
53,071
78,975Product revenue—
—
28,949Costs and operating expense:




   Cost of Biosecurity service revenue28,897
38,549
46,524   Cost of Biosecurity product revenue—
—
7,481   Research and development—
771
1,599   General and administrative27,443
44,370
55,514Biosecurity operating (loss) income(18,931)
(30,619)
(3,194)Total segment operating loss(114,461)
(249,186)
(366,816)Reconciling items to reconcile total segment operating loss to loss before income taxes:Stock-based compensation (1)82,704
115,299
234,908Impairment expense (2)—
53,654
121,404Depreciation and amortization58,990
63,020
70,507Restructuring charges (3)11,398
24,172
—Carrying cost of excess space (net of sublease income) (4)53,723
25,986
—Merger and acquisition related expenses (5)(5,998)
4,417
61,188Acquired in-process research and development—
19,849
9,582Other (income) expense, net (6)(1,678)
(8,075)
28,535Loss before income taxes$     (313,600)
$     (547,508)
$     (892,940)

(1)Includes $1.2 million, $3.0 million, and $5.0 million in related employer payroll taxes for the years ended December 31, 2025, 2024, and 2023, respectively.(2)For 2024, includes $47.9 million related to goodwill impairment and $5.8 million related to lab equipment. For 2023, includes a $25.2 million impairment loss on lab equipment and a $96.2 million impairment loss on lease assets associated with an exited Zymergen leased facility.(3)See Note 3, Restructuring, for composition of costs.(4)The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.(5)Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery.(6)Includes interest income, interest expense, loss on investments, losses/gains on deconsolidation of subsidiaries, changes in fair value of certain assets and liabilities, and other gains or losses.Non-GAAP Information In addition to our results determined in accordance with GAAP, we use earnings before interest, taxes, depreciation and amortization ("EBITDA") and Adjusted EBITDA internally to evaluate our performance and make financial and operational decisions. We believe these non-GAAP measures, when viewed with our GAAP results, may be helpful to investors in assessing our operating performance. We define EBITDA as net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders before the impact of interest income, interest expense, provision for income taxes and depreciation and amortization. We define Adjusted EBITDA as EBITDA adjusted for stock-based compensation expense, gain or loss on equity method investments, gain or loss on investments, change in fair value of warrant liabilities, gain or loss on deconsolidation of subsidiaries, transaction and integration costs associated with planned, completed or terminated mergers and acquisitions, including related litigation costs, restructuring and impairment charges (inclusive of impairments of goodwill and long-lived assets), costs associated with the bankruptcy filing of our former subsidiary, Zymergen (the "Zymergen Bankruptcy"), and certain other income and expenses. We believe that the use of EBITDA and Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends because it eliminates the effect of financing activities, investing activities, and certain non-cash charges and other items that are not related to our core operating performance or affect comparability period over period.Our non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for GAAP performance measures. These measures exclude significant expenses and income required by GAAP, which impacts their alignment with consolidated financial statements. They also rely on management's judgment to determine which items are included or excluded, making them inherently subjective. Additionally, non-GAAP measures lack uniform definitions and may differ from those used by other companies, limiting comparability. A reconciliation of EBITDA and Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure, is presented below:
Year Ended December 31,(in thousands)2025
2024Net loss (1)$       (312,763)
$       (547,029)Interest income(22,616)
(38,612)Interest expense—
94Income tax benefit(837)
(479)Depreciation and amortization58,990
63,020EBITDA(277,226)
(523,006)Stock-based compensation (2)82,704
115,299Impairment expense (3)—
53,654Restructuring charges (4)11,398
24,172Merger and acquisition related expenses (5)(5,998)
4,417Loss on investments16,411
28,827Loss on deconsolidation of subsidiaries—
7,013Change in fair value of warrant liabilities—
(5,701)Change in fair value of convertible notes5,685
2,014Adjusted EBITDA$       (167,026)
$       (293,311)

(1)All periods include non-cash revenue when earned. For the year ended December 31, 2025 this included $7.5 million in non-cash revenue from the release of a deferred revenue balance associated with the terminated BiomEdit, Inc. ("BiomEdit") contract. For the year ended December 31, 2024 this included $45.4 million recognized pursuant to the termination of revenue contracts with Motif and $4.5 million in non-cash revenue from the release of a deferred revenue balance associated with the termination of contract with a related party.(2)For the years ended December 31, 2025 and 2024, includes $1.2 million and $3.0 million, respectively, in related employer payroll taxes.(3)For 2024, includes $47.9 million related to goodwill impairment and $5.8 million related to lab equipment.(4)Restructuring charges consist of employee termination costs from the reduction in force commenced in June 2024, as well as the impairment of a right-of-use asset relating to facilities consolidation. (5)Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero and $19.8 million for the years ended December 31, 2025 and 2024, respectively. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-reports-fourth-quarter-and-full-year-2025-financial-results-announces-focus-on-autonomous-labs-offerings-and-divestiture-of-its-non-core-biosecurity-business-302699023.htmlSOURCE Ginkgo Bioworks

Original: Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural ProductsFebruary 18, 2026 8:00 AM
PR Newswire (US)

Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costsBOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs.







Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chemistry. In response, Invaio's platform discovers and develops peptide-based crop protection solutions that complement or offer potent alternatives to conventional chemistry while meeting growers' standards for efficacy, affordability, and ease of use.As a part of the commercialization of its peptide-based products, Invaio will leverage Ginkgo's platform and best-in-class microbial strains for protein production. Ginkgo's strains have been engineered to provide advanced starting points for protein and peptide-based products through industrial-scale fermentation. In this collaboration, Ginkgo will further optimize its strains and fermentation processes to deliver on Invaio's production goals."Ginkgo's technology offers us a clear path to manufacturing our peptides at scale," said Amy O'Shea, CEO of Invaio Sciences. "We are excited to partner with Ginkgo to develop much-needed next generation crop protection solutions for persistent pests and diseases."This collaboration demonstrates Invaio's commitment to developing scalable and cost effective peptide-based crop protection solutions that fits into and complements growers' existing practices. It highlights the value of Ginkgo's technologies in helping biotechnology companies efficiently optimize different stages of product development, including scale-up and manufacturing. As part of this program, Ginkgo will perform key protocols using its autonomous lab infrastructure, including Reconfigurable Automation Carts (RACs) and Catalyst automation software."At Ginkgo, we understand the urgency for next-generation agricultural solutions that can support growers, consumers and the planet," Jill Bradshaw, General Manager of Ginkgo's Microbial Solutions business unit says. "We are excited to work alongside our partners at Invaio to deliver a manufacturing strain and process that allows them to continue to focus on the discovery of next-generation biological solutions important to crop protection."Ginkgo's platform supports partners at various stages of scale-up and manufacturing: from production strain licensing and engineering to bioprocess development and scale-up.To learn more, visit Invaio.com or www.ginkgo.bio/ About Ginkgo Bioworks:Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.About Invaio Sciences:Invaio Sciences, a Flagship Pioneering company, is a bioplatform company accelerating the leap to nature-positive agriculture. Building on advances in human health and leveraging proprietary GenAI tools, Invaio is uniquely positioned to design and develop peptide solutions for crop health with performance on par to conventional crop protection chemistries, enabling farmers to both improve yields and use more natural solutions. By leading in nature-positive technologies, Invaio is addressing consumer demands and unlocking radical benefits for farmers and the environment, leaving every acre better today and for generations to come. For more information, please visit www.invaio.com or follow Invaio on LinkedIn.INVAIO SCIENCES CONTACT:
media@invaio.comGINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.comGINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.comForward-Looking Statements of Ginkgo BioworksThis press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.



View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-invaio-sciences-enter-collaboration-to-develop-manufacturing-technology-for-peptide-based-agricultural-products-302691304.htmlSOURCE Ginkgo Bioworks

Original: Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products

Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific BenchmarkFebruary 5, 2026 2:00 PM
PR Newswire (US)

Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratoryPreprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesisGPT-5-driven autonomous lab executed over 36,000 experimentsGinkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven scienceBOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free protein synthesis reaction costs by 40% relative to state of the art, while running 36,000 experimental conditions across six iterative cycles.







The study represents a real-world scientific application of Ginkgo's autonomous lab. The collaborators combined OpenAI's GPT-5 reasoning model with Ginkgo's cloud laboratory infrastructure, built from its reconfigurable automation carts (RAC) technology and Catalyst automation software, to design, execute, and analyze experiments in an iterative, closed-loop workflow. GPT-5 was given internet access, a computer with data analysis packages, experimental (meta)data from prior iterations, and a preprint describing state of the art, and was able to operate like an experimental scientist – designing experiments, analyzing results, and refining its approach in response. In six rounds of experiments over the course of six months, it was able to design lower cost cell-free protein synthesis reaction compositions than had been shown in the scientific literature previously."By pairing a frontier large language model with an autonomous lab, we found reaction compositions that are notably cheaper than prior state of the art," said Reshma Shetty, co-founder of Ginkgo Bioworks and co-author of the study. "We expect more and more experiments to be run on autonomous labs where reagent and consumables costs dominate the cost of an experiment. Lower cost reagents for protein production enable more data generation and thus more scientific progress per dollar spent."The autonomous lab achieved production of a standard benchmark protein, superfolder green fluorescent protein (sfGFP), at $422 per gram of protein in total reaction component costs, compared to a previously reported state of the art of $698 per gram, representing a 40% reduction under the experimental conditions described. Cell-free protein synthesis is widely used in biological research but has been limited by high material costs and complex optimization, making it an ideal stress test for autonomous experimentation."At OpenAI, this was the first time we were able to interface a frontier model with an autonomous lab to carry out experimentation at a very large scale," said Joy Jiao, life sciences research lead at OpenAI and co-corresponding author of the study. "This success points to how AI systems can augment the experimental workflow, contributing to hypothesis generation, testing, and refinement based on real-world data."The autonomous lab executed more than 580 384-well plates, tested 36,000 reaction compositions, and generated nearly 150,000 experimental data points. Human involvement was primarily limited to reagent preparation, loading and unloading and system oversight, while experimental design, execution data interpretation, and hypothesis generation were handled by the GPT-5-driven autonomous lab. Notably, the model also proposed and prioritized new reagents to test, some of which independently anticipated findings from published research it had not been given access to.To preclude the AI from proposing impractical, invalid, or hallucinatory experiments, every design was validated against a Pydantic model before execution, including checking plate layout, standards, controls, replication, reagent availability, and volume constraints. Only experiments that passed validation were eligible to run. Additional scoring prioritized scientific rigor and consideration of prior results. GPT-5 generated human-readable lab notebook entries documenting its analysis, observations, and rationale, providing transparency into its reasoning."This is AI doing real experimental science: designing experiments, running them, and learning from the results," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "AI combined with autonomous labs is needed to keep the United States competitive in science worldwide – the recently announced Genesis Mission led by the U.S. Department of Energy to bring AI into science is leading the way here and I'm excited that our results with OpenAI show this approach is working."The Pydantic model is being released open source and the AI-improved cell-free reaction mix can be ordered by the scientific community at https://reagents.ginkgo.bio/About the Preprint
The findings are described in a scientific preprint that has not yet undergone peer review. The full manuscript, "Using a GPT-5-driven autonomous lab to optimize the cost and titer of cell-free protein synthesis," is available on OpenAI's website and will soon be available on bioRxiv.About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X ( @&h=3759204680&u=https%3A%2F%2Fx.com%2Fginkgo&a=Ginkgo" target="_blank" rel="nofollow">Ginkgo and @&h=906082279&u=https%3A%2F%2Fx.com%2FGinkgo_Biosec&a=Ginkgo_Biosec" target="_blank" rel="nofollow">Ginkgo_Biosec), Instagram ( @&h=1543668742&u=https%3A%2F%2Fwww.instagram.com%2Fginkgobioworks%2F&a=GinkgoBioworks" target="_blank" rel="nofollow">GinkgoBioworks), Threads ( @&h=3650846492&u=https%3A%2F%2Fwww.threads.com%2F%40ginkgobioworks&a=GinkgoBioworks" target="_blank" rel="nofollow">GinkgoBioworks), or LinkedIn.Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's autonomous laboratories. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.ContactsGinkgo Bioworks investor contact:
investors@ginkgobioworks.comGinkgo Bioworks media contact:
press@ginkgobioworks.com










View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-autonomous-laboratory-driven-by-openais-gpt-5-achieves-40-improvement-over-state-of-the-art-scientific-benchmark-302680619.htmlSOURCE Ginkgo Bioworks

Original: Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

DNA, new 52 week low

DNA 10Q due TUEsday 2/25

DNA still climbing

DNA

DNA just hit over sold area $8.70 that is .22 before the 1:40 R/S should go back up $11.00 soon

DNA under $10

DNA, 10 day hourly

cheap

DNA under $10

DNA 10 day hourly post reverse split

Cascade (Gates) top holder

DNA new. 52 w eek low

DNA new 52/week low

DNA new 52 week low

DNA new 52 week low

even after 1:40 R/S DNA still has too many shares outstanding and corporate insiders have poorly mismanaged the company.
Ginkgo Bioworks needs complete restructure and less corporate greed. Some of their founders sell shares daily as they where gifted too many.
I stopped buying long ago and waiting to see if management can get their act together - they all deserve a pay cut!

DNA new 52 low

Interesting stock bought a few for tracking
To see what the crawdads do

poor management as they falsely pumped this stock now passing R/S effective Aug. 20
They also know they committed fraud and had to pass = 2. Officer Exculpation Proposal

Item 2 was to approve Article VIII of the Company’s Amended and Restated Certificate of Incorporation to permit officer exculpation (the “Officer Exculpation Proposal”), designated to be voted upon by the holders of Class A common stock and Class B common stock, voting together as a single class. The results of the vote were as follows:

exculpation
noun
a defense of some offensive behavior or some failure to keep a promise etc.
his transparent self-justification was unacceptable
the act of freeing from guilt or blame

bio scam….

https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-hold-special-meeting-of-shareholders-302210173.html

Sometimes I wonder if big names get kickbacks in exchange for their names being used??

Cathy led her sheep 🐑 to slaughter!! Worst performing IPO I've ever seen!!

😂😂😂😂😂😂😂

ARK dumped all holdings. I am out. Cut my losses.

It will reverse split because there is no choice

Average down or cut losses?

DNA new 52 week low

Timber!!

Bought a few

R/S will be announced without warning!! Proceed with caution!!

Yes, new low and very unhappy with DNA management. They were too slow to start restructuring and they still have one of the founders selling stock daily - what does he know?

DNA new 52 week low

I appreciate the response and opinion. I would like to think we would get a small bounce upward from here before a possible RS....

Got in low...
Bounce ready.

I feel we are close to bottom possible around.50 as lots of shorts took this down fast. We know DNA is in restructuring mode, which they should have done a long time ago. We still have one of their founders selling shares daily which should be in their ethic guidance as he most likely has inside info on R/S soon.

Long term I am positive but unhappy with management.

Is this the bottom?

Acknowledge Me!! Lol 😂

Yep, yet another SPAC born public company that's in the toilet, I fore see a reverse announcement coming very soon, given they've received a listing standard Notice form the NYSE...

DNA new 52 week low

I'll take that as a no!! Lol 😂 The Cathy curse continues!!

Still happy??

Why DNA will keep going down is all the insider selling from page 43 of last finacials: Austin has been selling shares daily so it is founders driving the price below SEC requirements of min of $1.00
Ginkgo’s Founders currently own nearly 20% of the outstanding shares of Ginkgo, the vast majority of which are in Class B shares
? Class B shares are not freely tradable (must be converted to Class A) and are often not shown on automated data services
? As such, these aggregation services (such as Bloomberg or Yahoo) can be unhelpful in determining actual holdings of certain investors, including
our Founders, who may hold different classes of shares which may not be included

Founder sales through April 29, 2024 relative to total holdings(1)
Mandatory Sell-to-Cover(2) 10b5-1 plan
Shares sold
(in millions) % of holdings
Shares sold
(in millions) % of holdings
Jason (CEO) 12.3 11.3% 10.4 9.6%
Reshma (COO) 12.3 11.4% 1.9 1.8%
Barry (CTO) 12.3 11.2% 1.9 1.7%
Austin 12.3 11.3% 0.9 0.8